The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Svechnikova E.V.

Novosibirsk State Medical University

Marshani Z.B.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Fomin K.A.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Vladimirsky Moscow Regional Research Clinical Institute

Evdokimov E.Yu.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Central Research Institute of Epidemiology

Genetically engineered biological drugs in psoriasis treatment in the COVID-19 pandemic

Authors:

Svechnikova E.V., Marshani Z.B., Fomin K.A., Evdokimov E.Yu.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(5): 95‑101

DOI: 10.17116/klinderma20212005195

Read: 3185 times

Download PDF (RU)
Contact the author
Table of contents

GENETICALLY ENGINEERED BIOLOGICAL DRUGS IN PSORIASIS TREATMENT IN THE COVID-19 PANDEMIC
GENETICALLY ENGINEERED BIOLOGICAL DRUGS IN PSORIASIS TREATMENT IN THE COVID-19 PANDEMIC

To cite this article:

Svechnikova EV, Marshani ZB, Fomin KA, Evdokimov EYu. Genetically engineered biological drugs in psoriasis treatment in the COVID-19 pandemic. Russian Journal of Clinical Dermatology and Venereology. 2021;20(5):95‑101. (In Russ.)
https://doi.org/10.17116/klinderma20212005195

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
A clinical case of the aortic rupture after SARS-CoV-2 in the patient with Stickler syndrom. Russian Journal of Preventive Medi­cine. 2025;(3):103-106
Post-COVID syndrome: orga­nizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medi­cine. 2025;(1):65-72
Coro­navirus infe­ction as a risk factor in occlusive-stenotic lesions of the brachiocephalic arte­ries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52
mRNA cancer vaccines: features of problems and collisions. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):3-16
SpO2/RR index in choosing the method for correction of acute respiratory failure in COVID-19 patients. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):50-58
Post-Covid aortitis with cardiac invo­lvement: progressive aortic aneurysm combined with active myocarditis. Russian Journal of Archive of Pathology. 2025;(2):53-58
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemo­dynamics, vege­tative regu­lation, resu­lts of psychological and stress resi­stance testing among students depe­nding on the COVID-19 presence in their medi­cal history. Russian Journal of Preventive Medi­cine. 2025;(4):94-101
Abstract:

In a relatively short period of its existence the new coronavirus has had a huge impact on the health care system and social infrastructure all over the world. Despite the fact that for the majority of those infected the disease is asymptomatic or mild, in a number of patients the infection becomes threatening and can lead to death. Among the risk factors for an unfavorable outcome the senior age, the presence of comorbidities and, presumably, immunosuppression were identified. This situation concerned the dermatological practice where a number of patients need the long-term immunosuppressive therapy. Patients with psoriasis receiving genetically engineered biological drugs (GEBDs) make up a significant proportion of this cohort and discontinuation of this treatment can lead to negative consequences. The accumulated knowledge suggests that the use of certain GEBPs not only does not increase the risks of COVID-19 but can also beneficially affect the underlying cytokine storm. Thus, during a pandemic the dermatologists all over the world were faced with the question of possibility and feasibility to continue the GEBP usage in patients with psoriasis. The article describes the characteristics of coronavirus, pathogenesis, clinical manifestations and diagnostics of COVID-19, and also considers the available data on continuing genetically engineered therapy in patients with psoriasis. In addition, the article presents its own observations on new coronavirus infection in patients with psoriasis receiving GEBDs.

Keywords:

SARS-CoV-2
COVID-19
psoriasis
genetically engineered biological drugs
IL-17 inhibitor

Authors:

Svechnikova E.V.

Novosibirsk State Medical University

Marshani Z.B.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Fomin K.A.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Vladimirsky Moscow Regional Research Clinical Institute

Evdokimov E.Yu.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Central Research Institute of Epidemiology

Received:

03.03.2021

Accepted:

12.08.2021

Close metadata

References:

  1. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Front Pharmacol. 2020;11:117. Published 2020 Feb 25.  https://doi.org/10.3389/fphar.2020.00117
  2. Kearns DG, Uppal S, Chat VS, Wu JJ. Use of systemic therapies for psoriasis in the COVID-19 era (published online ahead of print, 2020 May 27). J Dermatolog Treat. 2020; ahead-of-print: 1-4.  https://doi.org/10.1080/09546634.2020.1775774
  3. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6): 1605-1613. https://doi.org/10.4049/jimmunol.1800013
  4. Cohen JM, Perez-Chada LM, De Kouchkovsky D & Gehlhausen JR. Psoriasis and COVID-19: a multifactorial consideration. Journal of Dermatological Treatment. 2020; ahead-of-print: 1-1.  https://doi.org/10.1080/09546634.2020.1782818
  5. Shahidi-Dadras M, Tabary M, Robati RM, Araghi F & Dadkhahfar S. Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)? Journal of Dermatological Treatment. 2020; ahead-of-print:1-7.  https://doi.org/10.1080/09546634.2020.1782819
  6. Stein RA. COVID-19 and rationally layered social distancing. Int J Clin Pract. 2020;74(7):e13501. https://doi.org/10.1111/ijcp.13501
  7. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.  https://doi.org/10.1016/j.jaad.2016.07.064
  8. Mikhaylov D, Hashim PW, Nektalova T, Goldenberg G. Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. J Clin Aesthet Dermatol. 2019;12(6):46-54. 
  9. Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017;13:315-323. Published 2017 Mar 13.  https://doi.org/10.2147/TCRM.S111107
  10. Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868. Published 2019 Aug 14.  https://doi.org/10.1371/journal.pone.0220868
  11. Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28(4):179-193.  https://doi.org/10.1111/dth.12251
  12. Malakouti M, Jacob SE, Anderson NJ. Treatment challenges in the management of moderate-to-severe plaque psoriasis — role of secukinumab. Clin Cosmet Investig Dermatol. 2016;9:347-355. Published 2016 Oct 11.  https://doi.org/10.2147/CCID.S81160
  13. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6): 535-545.  https://doi.org/10.4161/mabs.3.6.17815
  14. Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL) [published online ahead of print, 2020 May 4]. J Eur Acad Dermatol Venereol. 2020;10:2566-2573. https://doi.org/10.1111/jdv.16568
  15. Zwicky P, Unger S, Becher B. Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. J Exp Med. 2020;217(1):e20191123. https://doi.org/10.1084/jem.20191123
  16. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432.  https://doi.org/10.1002/jmv.25685
  17. Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5): 173-175.  https://doi.org/10.1016/j.jaad.2020.03.046
  18. Nogueira M, Vender R, Torres T. Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs Context. 2020;9:2020-4-10. Published 2020 May 14.  https://doi.org/10.7573/dic.2020-4-10
  19. Chat VS, Uppal SK, Kearns DG & Wu JJ. Clinical management of psoriasis patients during the COVID-19 pandemic. Journal of Dermatological Treatment. 2020;Jun 22;1-2.  https://doi.org/10.1080/09546634.2020.1781045
  20. Rider P, Carmi Y, Cohen I. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol. 2016;2016:9259646. https://doi.org/10.1155/2016/9259646
  21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (published correction appears in Lancet. 2020 Jan 30). Lancet. 2020;395(10223):497-506.  https://doi.org/10.1016/S0140-6736(20)30183-5
  22. Galluzzo M, Tofani L, Bianchi L, Talamonti M. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert Opin Biol Ther. 2020;20(8):829-830.  https://doi.org/10.1080/14712598.2020.1779217
  23. Ghazawi FM, Lim M, Dutz JP, Kirchhof MG. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration (published online ahead of print, 2020 Jul 3). Int J Dermatol. 2020;59(9):1043-1056. https://doi.org/10.1111/ijd.15028
  24. Statement on the coronavirus (COVID-19) Outbreak. International Psoriasis Council. 2020 Mar 11.  https://www.psoriasiscouncil.org
  25. Freeman EE, McMahon DE, Fitzgerald M, et al. Modernizing clinical practice guidelines for the American Academy of Dermatology. J Am Acad Dermatol. 2020;82(6):1487-1489. https://doi.org/10.1016/j.jaad.2019.12.075
  26. Foundation NP. NPF Medical Board COVID-19 Recommendations for Patients with Psoriatic Disease (Internet). 2020 (cited 2020 Mar 23). https://www.psoriasis.org/advance/coronavirus
  27. Dopytalska K, Mikucka-Wituszyńska A, Ciechanowicz P, Szczerba M, Szymańska E, Walecka I. Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw (published online ahead of print, 2020 Jun 26). J Dermatolog Treat. 2020;Jun 26;1-5.  https://doi.org/10.1080/09546634.2020.1782822
  28. Vsemirnaya organizatsiya zdravookhraneniya, elektronnyi resurs. (In Russ.). https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  29. Freeman EE, McMahon DE. Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease. J Am Acad Dermatol. 2020;82(6):231-232.  https://doi.org/10.1016/j.jaad.2020.04.002
  30. Recommendations for systemic therapy in persons with psoriasis during the pandemic phase of SARS-CoV-2 (corona virus). Task force of the advisory boards of PsoBest, PsoNet and Deutscher Psoriasisbund eV.  https://www.psobest.de/wp-content/uploads/2020/03/RundschreibenPsoBestPsoNetCoronafinalengl.1.1.pdf
  31. Italian Society of Dermatology SiDeMaST. Coronavirus: Vademecum per i Pazienti affetti da Psoriasi Cutanea E/o Artropatia Psoriasica. blog/infezione-da-coronavirus-vademecum-per-i-pazienti-affetti-da-psoriasi-cutanea-e-o-artropatia-psoriasica/
  32. French Society of Dermatology/Societe Francaise de Dermatologie (SFD). Recommandations pour le déconfinement des patients atteints de maladies auto-immunes ou auto-inflammatoires 7 mai 2020. https://www.fai2r.org/wp-content/uploads/2020/03/19032020_COVID19-Recos-patients-FAI2R.pdf
  33. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan (published correction appears in Emerg Microbes Infect. 2020 Dec;9(1):540). Emerg Microbes Infect. 2020;9(1):221-236. Published 2020 Jan 28.  https://doi.org/10.1080/22221751.2020.1719902
  34. Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. N Engl J Med. 2020; 383(1):85-88.  https://doi.org/10.1056/NEJMc2009567
  35. Roshanravan N, Seif F, Ostadrahimi A, Pouraghaei M, Ghaffari S. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review (published online ahead of print, 2020 Jun 19). Arch Med Res. 2020;S0188-4409(20)30590-7.  https://doi.org/10.1016/j.arcmed.2020.06.012
  36. Ouédraogo DD, Tiendrébéogo WJS, Kaboré F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clin Rheumatol. 2020;39(7):2069-2075. https://doi.org/10.1007/s10067-020-05189-y
  37. Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges and hopes (published online ahead of print, 2020 Jul 11). Life Sci. 2020;257:118054. https://doi.org/10.1016/j.lfs.2020.118054
  38. Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020;34(8):360-361.  https://doi.org/10.1111/jdv.16587
  39. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234): 1407-1409. https://doi.org/10.1016/S0140-6736(20)30858-8
  40. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19 (published online ahead of print, 2020 Jul 21). Drugs. 2020 Sep;80:1267–1292. https://doi.org/10.1007/s40265-020-01367-z
  41. Tursi A, Vetrone LM, Papa A. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19. Inflamm Bowel Dis. 2020;26(7):e73.  https://doi.org/10.1093/ibd/izaa114
  42. Ma WT, Yao XT, Peng Q, Chen DK. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9(7):190109. https://doi.org/10.1098/rsob.190109
  43. Torres T, Puig L. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Am J Clin Dermatol. 2020;21(3):307-311.  https://doi.org/10.1007/s40257-020-00514-2
  44. Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018;9:1682. Published 2018 Aug 2.  https://doi.org/10.3389/fimmu.2018.01682
  45. Bulat V, Situm M, Azdajic MD, Likic R. Potential role of IL-17 blocking agents in the treatment of severe COVID-19? (published online ahead of print, 2020 Jul 5). Br J Clin Pharmacol. 2020;87(3):1578-1581. https://doi.org/10.1111/bcp.14437
  46. Mendoza VMM. Interleukin-17: A potential therapeutic target in COVID-19. J Infect. 2020;81(2):136-138.  https://doi.org/10.1016/j.jinf.2020.05.072
  47. Timis TL, Florian IA, Vesa SC, Orasan RI. Treatment of psoriasis — unburdened by fear during SARS-CoV2 menace (published online ahead of print, 2020 Jul 3). J Dermatolog Treat. 2020;ahead-of-print:1-4.  https://doi.org/10.1080/09546634.2020.1788704
  48. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges (published online ahead of print, 2020 Jul 6). J Dermatolog Treat. 2020;ahead-of-print:1-5.  https://doi.org/10.1080/09546634.2020.1789051
  49. Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374.  https://doi.org/10.1111/bjd.19158
  50. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration (published online ahead of print, 2020 May 1). Dermatol Ther. 2020;e13475. https://doi.org/10.1111/dth.13475
  51. Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G. Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment (published online ahead of print, 2020 May 30). Dermatol Ther. 2020;e13706. https://doi.org/10.1111/dth.13706
  52. Fougerousse AC, Perrussel M, Bécherel PA, et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19 (published online ahead of print, 2020 Jun 21). J Eur Acad Dermatol Venereol. 2020;23(11):676-679.  https://doi.org/10.1111/jdv.16761
  53. Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-294.  https://doi.org/10.1016/j.jaad.2020.04.165
  54. Holcomb ZE, Santillan MR, Morss-Walton PC, et al. Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy (published online ahead of print, 2020 Jul 1). J Am Acad Dermatol. 2020;S0190-9622(20)32099-5.  https://doi.org/10.1016/j.jaad.2020.06.999
  55. Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. Journal of Dermatological Treatment. 2020;31(4):328-329.  https://doi.org/10.1080/09546634.2020.1757605
  56. Brownstone ND, Thibodeaux QG, Reddy VD, et al. Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Dermatol Ther (Heidelb). 2020;10(4):881-885.  https://doi.org/10.1007/s13555-020-00394-8
  57. Valenti M, Facheris P, Pavia G, et al. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab (published online ahead of print, 2020 May 30). Dermatol Ther. 2020;e13708. https://doi.org/10.1111/dth.13708
  58. Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(8): 357-358.  https://doi.org/10.1111/jdv.16571
  59. Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(6):254-255.  https://doi.org/10.1111/jdv.16468
  60. Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain (published online ahead of print, 2020 Jul 3). Dermatol Ther. 2020;e13961. https://doi.org/10.1111/dth.13961
  61. Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320-321.  https://doi.org/10.1080/09546634.2020.1749545
  62. Lippi G, Mattiuzzi C, Bovo C, Plebani M. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed. 2020;91(2):137-145. Published 2020 May 11.  https://doi.org/10.23750/abm.v91i2.9548
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.